ReviewFrontiers in cellular and infection microbiology2015
Approaches to treatment of emerging Shiga toxin-producing Escherichia coli infections highlighting the O104:H4 serotype.
Review in Frontiers in cellular and infection microbiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 60 citations in OpenAlex.
- Antibody Screening and Binding Prediction Analysis Targeting Stx2.Antibodies (Basel, Switzerland) · 2026Article
- Genomic Markers Distinguishing Shiga Toxin-ProducingPathogens (Basel, Switzerland) · 2025Article
- DiarrheagenicInternational journal of molecular sciences · 2024Article
- Do asymptomatic STEC-long-term carriers need to be isolated or decolonized? New evidence from a community case study and concepts in favor of an individualized strategy.Frontiers in public health · 2024Article
- Prevalence and Implications of Shiga Toxin-ProducingPathogens (Basel, Switzerland) · 2022Review
- Evaluating the Phenotypic and Genomic Characterization of Some Egyptian Phages Infecting Shiga Toxin-ProducingBiology · 2022Article
- Genome Sequence Analysis and Characterization of Shiga Toxin 2 Production byFrontiers in cellular and infection microbiology · 2022Article
- Mucosal IFNγ production and potential role in protection in Escherichia coli O157:H7 vaccinated and challenged cattle.Scientific reports · 2021Article
- Role of Recent Therapeutic Applications and the Infection Strategies of Shiga Toxin-ProducingFrontiers in cellular and infection microbiology · 2021Review
- Review
- Stable Neutralization of a Virulence Factor in Bacteria Using Temperate Phage in the Mammalian Gut.mSystems · 2020Article
- Pathogenomes of Atypical Non-shigatoxigenicFrontiers in microbiology · 2020Article
- Treatment Strategies for Infections With Shiga Toxin-ProducingFrontiers in cellular and infection microbiology · 2020Review
- Properties of an Antimicrobial Molecule Produced by anAntibiotics (Basel, Switzerland) · 2019Article
- Anti-biofilm and Antibacterial Activity ofIndian journal of microbiology · 2019Article
- Management of STEC Gastroenteritis: Is There a Role for Probiotics?International journal of environmental research and public health · 2019Review
- Bacteriophages Reduce PathogenicFrontiers in microbiology · 2019Article
- Competition amongVeterinary sciences · 2018Article
- Ribosome maturation by the endoribonuclease YbeY stabilizes a type 3 secretion system transcript required for virulence of enterohemorrhagicThe Journal of biological chemistry · 2018Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Shiga toxin-producing Escherichia coli (STEC) are a group of diarrheagenic bacteria associated with foodborne outbreaks. Infection with these agents may result in grave sequelae that include fatality. A large number of STEC serotypes has been identified to date. E. coli serotype O104:H4 is an emerging pathogen responsible for a 2011 outbreak in Europe that resulted in over 4000 infections and 50 deaths. STEC pathogenicity is highly reliant on the production of one or more Shiga toxins that can inhibit protein synthesis in host cells resulting in a cytotoxicity that may affect various organ systems. Antimicrobials are usually avoided in the treatment of STEC infections since they are believed to induce bacterial cell lysis and the release of stored toxins. Some antimicrobials have also been reported to enhance toxin synthesis and production from these organisms. Various groups have attempted alternative treatment approaches including the administration of toxin-directed antibodies, toxin-adsorbing polymers, probiotic agents and natural remedies. The utility of antibiotics in treating STEC infections has also been reconsidered in recent years with certain modalities showing promise.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.